IP Library › Granted Patent US 9,511,101
Granted Patent B2
US 9,511,101 · App. 14/727,487 · Granted Dec 6, 2016

Compositions and methods for treatment of microbial infections

Inventors: Jiri Pillich (Brno, CZ); John C. Balcarek (Huntsville, AL)
Assignee: IMMUNOLOGY LABORATORIES, INC.
A61K35/741A61K9/0019A61K39/02A61K39/0266A61K39/085A61K39/092A61K39/104A61K39/12C12N7/00C12P1/04A61K2039/521A61K2039/54A61K2039/545A61K2039/57A61K2039/58C12N2795/00011C12N2795/00034C12N2795/00071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,511,101
App. No.
14/727,487
Granted
Dec 6, 2016
Kind
B2
Abstract

The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.

Claims (18)

1. A method of treating a Staphylococcus aureus ( S. aureus ) infection in humans or animals, comprising, administering to a human or animal having said infection, a composition comprising one or more proteins from a 50 kDa fraction isolated from a bacterial lysate derived from the infection of at least one bacterial strain of S. aureus , deposited with the Czech Collection of Microorganisms (CCM) under accession number CCM 4995 or CCM 4997 or both CCM 4995 and CCM 4997 with at least one bacteriophage deposited with the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmBH (DSM) having accession number DSM14614, DSM 14615, or DSM 14616.

2. The method of claim 1 , wherein the composition is a pharmaceutical composition further comprising a pharmaceutical excipient.

3. The method of claim 1 , wherein the composition further comprises an adjuvant.

4. The method of claim 1 , wherein the infection comprises chronic upper respiratory disease, mastitis, wound infection, osteomyelitis, endocarditis, skin polymicrobial infections, bronchial asthma, chronic sinusitis, cystic fibrosis or acne vulgaris.

5. The method of claim 1 , wherein the composition is administered subcutaneously, intradermally, intramuscularly, nasally, topically or parenterally.

6. The method of claim 1 , wherein the composition is administered prophylactically.

7. The method of claim 1 , wherein the composition is administered more than one time.

8. The method of claim 1 , wherein the composition is administered more than one time by one or more than one administration route.

9. A method of vaccination for altering a Staphylococcus aureus ( S. aureus ) infection or pathological conditions resulting from said S. aureus infection comprising administering at least one time to a human or animal a composition comprising one or more protein from a 50 kDa fraction isolated from a bacterial lysate derived from the infection of at least one bacterial strain of S. aureus deposited with the Czech Collection of Microorganisms (CCM) under accession number CCM 4995 or CCM 4997 or both CCM 4995 and CCM 4997with a bacteriophage deposited with the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmBH (DSM) having accession number DSM 14614, DSM 14615, or DSM 14616.

10. The method of claim 9 , wherein the composition is a pharmaceutical composition further comprising a pharmaceutical excipient.

11. The method of claim 9 , wherein the composition further comprises an adjuvant.

12. The method of claim 9 , wherein the infection is chronic upper respiratory disease, mastitis, wound infection, osteomyelitis, endocarditis, skin polymicrobial infections, bronchial asthma, chronic sinusitis, cystic fibrosis or acne vulgaris.

13. The method of claim 9 , wherein the composition is administered subcutaneously, intradermally, intramuscularly, nasally, topically or parenterally.

14. The method of claim 9 , wherein the composition is administered prophylactically.

15. The method of claim 9 , wherein the composition is administered more than one time.

16. The method of claim 9 , wherein the composition is administered more than one time by one or more than one administration route.

17. The method of claim 1 , wherein at least one of the one or more proteins comprises a phage capsid protein.

18. The method of claim 9 , wherein at least one of the one or more proteins comprises at phage capsid protein.

Continuity (8)
Continuation 13954580 · Jul 30, 2013
Division 13280049 · Oct 24, 2011
Division 11986715 · Nov 26, 2007
Continuation In Part 11170972 · Jun 30, 2005
Continuation 10367213 · Feb 13, 2003
Provisional Application 60860912 · Nov 24, 2006
Provisional Application 60356483 · Feb 13, 2002
Related Publication 20160008454A1 · Jan 14, 2016